Importance of long-term monitoring of patients with breast reconstructions: a case of 10-year cancer recurrence

Sarah Hardwick\textsuperscript{a}, Sanjeev Hariparsad\textsuperscript{b}, Nakul Kain\textsuperscript{b} and Charles M. Malata\textsuperscript{a,b,c}

\textsuperscript{a}Cambridge Breast Unit, Addenbrooke’s University Hospital, Cambridge, UK; \textsuperscript{b}Plastic & Reconstructive Surgery Department, Addenbrooke’s University Hospital, Cambridge, UK; \textsuperscript{c}Postgraduate Medical Institute at Anglia Ruskin University, Cambridge & Chelmsford, UK

ABSTRACT

We report a case of breast cancer recurrence in a 41-year-old female ten years post mastectomy, and two years post tertiary DIEP flap reconstruction. Reconstructed patients, especially those with aggressive cancers, must be informed of long-term risk of recurrence and monitored long-term following mastectomy and reconstruction.

ARTICLE HISTORY

Received 23 April 2020
Accepted 22 November 2021

KEYWORDS

Breast cancer recurrence; breast cancer monitoring

Introduction

Breast cancer has a long-term recurrence risk with a local recurrence rate in a mixed cohort of wide local excision and mastectomy patients of 1.0–1.5% per year for 15–20 years [1]. Whilst mastectomy patients are considered to have the lowest risk, the lifetime risk of recurrence remains in the range of 2.3–5.0% [2]. Cancer histology, stage, grade, lymph node status, commercially available gene expression genomic classifiers, and clinical factors are all used to predict a patient’s long-term risk of recurrence. It has been well established in patients undergoing ablative surgery that the majority of breast cancers recur within the first 5 years [3–6]. Risk of recurrence increases with higher tumour grade, positive nodal status, and certain histological subtypes; higher rates of local recurrence are reported among Her2 positive, triple negative, and ductal carcinoma in situ containing histology in patients undergoing breast conserving surgery [7]. Local recurrence is rare in patients who undergo mastectomy for ductal carcinoma [8–10]. After mastectomy, lymph node status and tumour size are the dominant risk factors for local recurrence [8], with an increased risk demonstrated in one retrospective study in young patients, those with ductal carcinoma tumour subtypes, high grade tumours, and evidence of microinvasion [11]. Recurrences more than 10 years after oncological surgery are especially rare [12].

In recent decades, outcomes of breast cancer management have focused not only on surgical and oncological clearance but also on the aesthetics of partial or total breast reconstruction. Whilst reconstruction has greatly improved patient quality of life and psychological outcomes following oncological breast surgery, it may mask clinical and radiological detection of breast cancer recurrence. Fat necrosis can occur secondary to hypoxia in flaps used in autologous tissue based reconstruction. Post-operative fat necrosis occurs in 6–18% of deep inferior epigastric perforator flap (DIEP) and 10–24% of transverse rectus abdominis musculocutaneous flap (TRAM) reconstructions [13]. On clinical examination, the physical manifestation of necrosis is a firm palpable mass that may mimic a recurrent tumour. On imaging, it can appear as a smooth bordered lucent mass resembling a cyst or, less commonly, as pleomorphic calcifications, which render its differentiation from recurrent tumour more difficult [14]. A biopsy is mandatory to investigate suspicious findings on imaging or physical examination [15].

We herein describe a case of breast cancer recurrence in a patient post DIEP and autologous fat grafting (AFG). Our patient presented with recurrent ductal cancer 10 years after mastectomy in the DIEP-
reconstructed breast and 18 months after AFG. Her case emphasises the importance of post-operative monitoring in patients with high grade invasive cancers, and the role oncological physicians, breast surgeons, and plastic surgeons play in concert communicating ongoing long term risks to patients post

Figure 1. Clinical photographs of the AP, right lateral and left oblique views of the patient before salvage surgery (a, d, g), after the DIEP flap (b, e, h) and after fat grafting (c, f, i) to the volume deficit and the contour deficiency especially in the take-off superiorly.
reconstruction. Plastic surgeons may see patients later in their treatment journey than the oncological breast surgeons for secondary (delayed) or tertiary breast reconstruction, and therefore have an important role in emphasising both the importance of self-examination and adherence to local monitoring protocols post-operatively, even after curative surgical, radiological, and oncological treatments are complete.

Case presentation

A 41-year-old woman was diagnosed with right-sided breast cancer in 2003. She underwent skin-sparing mastectomy and axillary clearance, with immediate breast reconstruction (IBR) with an expandable implant (hereafter referred to as an expander). The histopathological results revealed an 8.4 mm grade 2 invasive ductal carcinoma with associated intermediate grade ductal carcinoma in-situ. The tumour was oestrogen, progesterone and HER2/NEU receptor positive, with clear resection margins and no vascular invasion. One out of 29 axillary lymph nodes examined was positive, giving her a Nottingham Prognostic Index score of 5.7. She therefore received postoperative chemotherapy and radiotherapy, as well as tamoxifen and anastrozole therapy which were completed in 2009. However, prior to receiving radiotherapy, an expander-to-implant exchange had to be performed earlier than planned due to spontaneous deflation of the expander. Despite this the patient remained unhappy with her reconstruction and was therefore referred to the plastic surgery service in 2010. Given her suboptimal reconstruction combined with radiation-induced capsular contracture, a totally autologous conversion to a free flap was undertaken [16]. This salvage surgery comprised total capsulectomy with implant removal and tertiary [16] reconstruction with a DIEP flap. A simultaneous contralateral balancing mastopexy was also performed (Figure 1: pre-salvage, post-salvage and post-fat grafting appearances). Histopathological analysis of the capsulectomy specimen, the mastectomy scar, and an incidental internal mammary lymph node showed no evidence of malignancy. The breast tissue from the contralateral mastopexy showed no abnormality.

Although symptoms from previous capsular contracture were resolved, the reconstructed breast was smaller than the opposite breast despite the simultaneous balancing surgery (Figure 1(b,e,h)). In 2011, she therefore underwent Coleman fat transfer from the abdomen to the right DIEP reconstruction, both into the deep and superficial layers of the DIEP flap. This was repeated 6 months later in 2012. In our institution, post-operative autologous tissue flap patients are counselled to perform monthly self-examination. Post mastectomy patients have routine follow up with the breast oncology team at least bi-annually for two years after oncological surgery, with increased frequency at patient or physician’s discretion, in line with NICE guidance [17]. They additionally have planned follow up with the plastic surgery team 1 year after reconstructive surgery. However routine imaging, such as screening mammography, is not routinely

---

Table 1. International guidance from major regulatory bodies in the US, UK, and Europe on recommended post-operative clinical and radiological examination frequency mastectomy for breast cancer.

| Guideline | History and clinical examination | Imaging onset: screening mammogram | Imaging frequency | Imaging frequency reduction and termination |
|-----------|---------------------------------|-----------------------------------|------------------|-------------------------------------------|
| ACR [19]  | No recommendation               | Contralateral 6–12 months post radiotherapy | Annual           | Institutions to decide when to return to routine breast cancer screening |
| ACS-ASCO [20] | 3–6 Months for first 3 years, Every 6–12 months for years 4–5, then annually | Contralateral >6 months post radiotherapy | Repeat every 6–12 months and reduce to annual if MMG stable | No recommendation |
| ESMO [21] | Every 3–4 months for first 2 years, Every 6 months years 3–5, then annually | Contralateral: onset timing not specified | Annual           | No recommendation |
| NICE [17] | Regular follow up appointments as stipulated by physician or patient | Not specified | Annual           | After 5 years if ≥/= NHS BSP screening age, frequency thereafter not specified |
| NCCN [22] | 4–6 Months for first 5 years then annually | Contralateral: 6–12 months after RT | Annual           | No recommendation |
| RCR [18]  | Not specified                   | Contralateral: onset not specified, Ipsilateral if high risk and recipient of autologous tissue reconstruction | Annual           | Consider reduced frequency age 50 and cessation age 75 |

Abbreviations: ACR: American College of Radiologists; ACS: American Cancer Society; ASCO: American Society of Clinical Oncology; ESMO: European Society of Medical Oncology; NICE: National Institute of Clinical Excellence; NHS BSP: National Health Service Breast Screening Programme; NCCN: National Comprehensive Cancer Network; RCR: Royal College of Radiologists.
performed, in line with guidance from the Royal College of Radiologists [18]. Therefore, as her two year term for follow up clinical examination with her oncolgical breast surgeon was complete, she had no routine follow up beyond her one year post-reconstruction appointment with the plastic surgery team, and no screening mammogram. In 2013, 18 months from her first fat grafting procedure and 10 years from the mastectomy, she noted two small lesions on self-examination in her right reconstructed breast— one in the upper inner quadrant and the other in the lower outer quadrant.

She was referred for urgent assessment to her oncological breast surgeon. As on clinical examination her new breast lumps were clinically different from the cysts/fat necrosis that can be expected following fat grafting, the patient underwent ultrasound guided biopsies of both lesions. These revealed a grade two invasive ductal carcinoma with oestrogen and HER2/NEU receptor positivity: recurrence of her original tumour. She underwent resection of the recurrent tumours, including the DIEP flap without further reconstruction. She remains well and disease-free 9 years later.

**Discussion**

While there is ample recommendation on when to commence follow up of imaging surveillance following mastectomy (Table 1) there is scant advice on ipsilateral imaging surveillance. Decisions about when to step down or reduce frequency of clinical examination and follow up are often left to the discretion of treating physicians. In a review of 18 publishing bodies [23] 13/18 did not recommend image screening the ipsilateral breast for recurrence, 5/18 provided no guidance, and only the United Kingdom Royal College of Radiologists recommended ipsilateral annual mammogram in the special case of high-risk patients; for example, extensive high grade DCIS close to a margin in autologous tissue reconstructed breasts [18]. Therefore late ipsilateral mastectomy site cancer recurrence, with or without breast reconstruction, may go undetected clinically until it is locally advanced or metastatic.

Locoregional recurrence risk in the reconstructed breast is similar to the risk after mastectomy alone, and reconstruction is not considered an oncologically provocative additional risk [24,25]. A retrospective review of 554 mammograms in 256 women who underwent TRAM flap reconstruction concluded that annual mammography in all autologous tissue based breast reconstructions yielded low additional detection rate of clinically occult malignancy, and concluded routine surveillance would not be beneficial [26]. The onus is therefore on individual treating physicians to proactively ensure recurrence is detected. This patient’s recurrence, occurring 10 years after primary oncological surgery, demonstrates the ongoing risk, and the role that plastic surgeons, who may see patients later in their recovery for delayed reconstruction, can fill in emphasising this ongoing risk. Whilst evidence to date argues against routine imaging screening in cancer patients who undergo ipsilateral breast reconstruction, late recurrence is still well-documented; Case reports of late recurrence post reconstruction have been published following DIEP flaps at 3 and 9 years post mastectomy in patients treated for intraductal carcinoma [15].

**Conclusion**

As long term recurrence is a well-established, if rare, and ongoing risk, the temporal relationship between reconstruction, fat grafting and recurrence will be complex. Based on cancer biology, we may assume that this patient’s recurrence was already present in a subclinical context, and that the imaging and additional examinations that followed late reconstruction and fat grafting simply expedited clinical detection. Cases such as ours [15] where interval follow up for delayed reconstruction facilitated detection of cancer recurrence, suggest an extension of the time window for repeat clinical examination in high risk patients may be warranted. Indeed this would likely be in accord with patients’ wishes; in a survey of breast cancer survivors, 56/84 indicated they would like to attend lifelong follow up [27]. However, as this is not universally clinically feasible, communication with patients on long term risk and the importance of self-examination is paramount. Identification of high risk sub-groups of mastectomy patients receiving delayed or salvage breast reconstruction could facilitate more personalised, extended post-operative follow up protocols. In the interim, plastic surgeons in the UK and internationally may wish to take up the Royal College of Radiologists’ guidance to perform annual mammograms for high risk patients with autologous tissue based reconstructions [18].

**Report limitations**

This patient was monitored according to the UK NICE [17] guidelines for follow up post oncological surgery
and Royal College of Radiologist guidelines [18] for imaging post autologous tissue based reconstruction. She received annual contralateral mammogram screening on the non-resected breast, but as she was not high risk for recurrence based on her clear resection margins, she did not receive ipsilateral screening mammograms following her DIEP flap. Her oncological surgery follow up was bi-annual for the first two years following mastectomy, and had long ceased by the time of her reconstructive surgery seven years later. Following recurrence, she was followed by the oncological breast surgeons biannually for a further two year period.

Disclosure statement
No potential conflict of interest was reported by the author(s).

References
[1] Bucchi L, Belli P, Benelli E, et al. Recommendations for breast imaging follow-up of women with a previous history of breast cancer: position paper from the Italian group for mammography screening (GISMa) and the italian college of breast radiologists (ICBR) by SIRM. Radiol Med. 2016;121(12):891–896.
[2] Freyvogel M, Padia S, Larson K, et al. Screening mammography following autologous breast reconstruction: an unnecessary effort. Ann Surg Oncol. 2014;21(10):3256–3260.
[3] Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–1232.
[4] Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738–2746.
[5] Petit JY, Gentilini O, Rotmensz N, et al. Oncological results of immediate breast reconstruction: long term follow-up of a large series at a single institution. Breast Cancer Res Treat. 2008;112(3):545–549.
[6] Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927–935.
[7] Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29(29):3885–3891.
[8] van der Leij F, Elkhuizen PH, Bartelink H, et al. Predictive factors for local recurrence in breast cancer. Semin Radiat Oncol. 2012;22(2):100–107.
[9] Childs SK, Chen YH, Duggan MM, et al. Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2013;85(4):948–952.
[10] Kim JH, Tavassoli F, Haffty BG. Chest wall relapse after mastectomy for ductal carcinoma in situ: a report of 10 cases with a review of the literature. Cancer J. 2006;12(2):92–101.
[11] Mamtani A, Nakhlis F, Downs-Canner S, et al. Impact of age on locoregional and distant recurrence after mastectomy for ductal carcinoma in situ with or without microinvasion. Ann Surg Oncol. 2019;26(13):4264–4271.
[12] Takeuchi H, Muto Y, Tashiro H. Clinicopathological characteristics of recurrence more than 10 years after surgery in patients with breast carcinoma. Anticancer Res. 2009;29(8):3445–3448.
[13] Hedegard W, Niell B, Specht M, et al. Breast reconstruction with a deep inferior epigastric perforator flap: imaging appearances of the normal flap and common complications. Radiographics. 2013;33(2):435–453.
[14] Pinel-Giroux FM, El Khoury MM, Trop I, et al. Breast reconstruction: review of surgical methods and spectrum of imaging findings. Radiographics. 2013;33(2):435–453.
[15] Huiskes JVM, Keemers-Gels ME, Fabré J, et al. DIEP flap breast reconstruction followed by local recurrence of breast cancer. Case Rep Oncol. 2018;11(2):493–498.
[16] Rabey NG, Lie KH, Kumiponjera D, et al. Salvage of failed prosthetic breast reconstructions by autologous conversion with free tissue transfers. Eplasty. 2013;13:e32.
[17] National Institute for Health and Care Excellence (NICE). 2017. NICE clinical guideline 164 [CG164]: familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. National Institute for Health and Care Excellence (NICE), Manchester. https://www.nice.org.uk/guidance/cg164.
[18] The Royal College of Radiologists. Guidance on screening and symptomatic breast imaging. Fourth edition. London: The Royal College of Radiologists; 2019.
[19] Mainiero MB, Moy L, Baron P, Expert Panel on Breast Imaging, et al. ACR appropriateness criteria® breast cancer screening. J Am Coll Radiol. 2017;14(11S):S383–S390.
[20] Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43–73.
[21] Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–v30.
[22] Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452–478.
[23] Swinnen J, Keupers M, Soens J, et al. Breast imaging surveillance after curative treatment for primary non-metastasised breast cancer in non-high-risk women: a systematic review. Insights Imag. 2018;9(6):961–970.
[24] Reddy S, Colakoglu S, Curtis MS, et al. Breast cancer recurrence following postmastectomy reconstruction compared to mastectomy with no reconstruction. Ann Plast Surg. 2011;66(5):466–471.

[25] Patterson SG, Teller P, Iyengar R, et al. Locoregional recurrence after mastectomy with immediate transverse rectus abdominis myocutaneous (TRAM) flap reconstruction. Ann Surg Oncol. 2012;19(8):2679–2684.

[26] Lee JM, Georgiann-Smith D, Gazelle GS, et al. Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology. 2008;248(2):398–405.

[27] de Bock GH, Bonnema J, Zwaan RE, et al. Patient’s needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer. 2004;90(6):1144–1150.